Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3
[Display omitted] •G9a was frequently upregulated in human HCC and associated with HCC aggressiveness.•G9a promoted HCC growth and metastasis both in vitro and in vivo.•Upregulation of G9a in HCC was attributed to gene amplification and loss of miR-1.•G9a epigenetically silenced the expression of tu...
Saved in:
Published in | Journal of hepatology Vol. 67; no. 4; pp. 758 - 769 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.10.2017
Elsevier Science Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | [Display omitted]
•G9a was frequently upregulated in human HCC and associated with HCC aggressiveness.•G9a promoted HCC growth and metastasis both in vitro and in vivo.•Upregulation of G9a in HCC was attributed to gene amplification and loss of miR-1.•G9a epigenetically silenced the expression of tumor suppressor gene RARRES3 in HCC.•Targeting G9a by small molecular inhibitors suppressed HCC growth.
Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated.
Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo.
We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a.
This study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment.
Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment. |
---|---|
AbstractList | Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated.BACKGROUND & AIMSHepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated.Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo.METHODSGene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo.We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a.RESULTSWe identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a.This study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment. Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment.CONCLUSIONThis study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment. Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment. Graphical abstract Deregulation of G9a in human HCC. G9a was frequently up-regulated in human HCC and implicated in HCC tumorigenesis and metastasis. The frequent up-regulation of G9a in human HCC was attributed to gene copy number gain at 6p21 and loss of miR-1. The oncogenic function of G9a was at least partially attributed to the epigenetic silencing of tumor suppressor RARRES3. Background & Aims Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated. Methods Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo. Results We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a. Conclusion This study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment. [Display omitted] •G9a was frequently upregulated in human HCC and associated with HCC aggressiveness.•G9a promoted HCC growth and metastasis both in vitro and in vivo.•Upregulation of G9a in HCC was attributed to gene amplification and loss of miR-1.•G9a epigenetically silenced the expression of tumor suppressor gene RARRES3 in HCC.•Targeting G9a by small molecular inhibitors suppressed HCC growth. Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated. Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo. We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a. This study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment. Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment. Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an important epigenetics regulator however, its role in liver carcinogenesis remains to be investigated. Gene expressions were determined by RNA-Seq and qRT-PCR. G9a knockdown and knockout cell lines were established by lentiviral-based shRNA and CRISPR/Cas9 gene editing system. Tumor-promoting functions of G9a was studied in both HCC cell lines and nude mice model. The downstream targets of G9a were identified by RNA-Seq and confirmed by ChIP assay. The therapeutic value of G9a inhibitors was evaluated both in vitro and in vivo. We identified G9a as a frequently upregulated histone methyltransferase in human HCCs. Upregulation of G9a was significantly associated with HCC progression and aggressive clinicopathological features. Functionally, we demonstrated that inactivation of G9a by RNAi knockdown, CRISPR/Cas9 knockout, and pharmacological inhibition remarkably abolished H3K9 di-methylation and suppressed HCC cell proliferation and metastasis in both in vitro and in vivo models. Mechanistically, we showed that the frequent upregulation of G9a in human HCCs was attributed to gene copy number gain at chromosome 6p21. In addition, we identified miR-1 as a negative regulator of G9a. Loss of miR-1 relieved the post-transcriptional repression on G9a and contributed to its upregulation in human HCC. Utilizing RNA sequencing, we identified the tumor suppressor RARRES3 as a critical target of G9a. Epigenetic silencing of RARRES3 contributed to the tumor-promoting function of G9a. This study shows a frequent deregulation of miR-1/G9a/RARRES3 axis in liver carcinogenesis, highlighting the pathological significance of G9a and its therapeutic potential in HCC treatment. Lay summary: In this study, we identified G9a histone methyltransferase was frequently upregulated in human HCC and contributes to epigenetic silencing of tumor suppressor gene RARRES3 in liver cancer. Targeting G9a may be a novel approach for HCC treatment. |
Author | Wei, Lai Wong, Chun-Ming Tsang, Felice Ho-Ching Lee, Joyce Man-Fong Wong, Carmen Chak-Lui Law, Cheuk-Ting Chiu, David Kung-Chun Ng, Irene Oi-Lin Cheng, Carol Lai-Hung Au, Sandy Leung-Kuen |
Author_xml | – sequence: 1 givenname: Lai surname: Wei fullname: Wei, Lai organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 2 givenname: David Kung-Chun surname: Chiu fullname: Chiu, David Kung-Chun organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 3 givenname: Felice Ho-Ching surname: Tsang fullname: Tsang, Felice Ho-Ching organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 4 givenname: Cheuk-Ting surname: Law fullname: Law, Cheuk-Ting organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 5 givenname: Carol Lai-Hung surname: Cheng fullname: Cheng, Carol Lai-Hung organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 6 givenname: Sandy Leung-Kuen surname: Au fullname: Au, Sandy Leung-Kuen organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 7 givenname: Joyce Man-Fong surname: Lee fullname: Lee, Joyce Man-Fong organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 8 givenname: Carmen Chak-Lui surname: Wong fullname: Wong, Carmen Chak-Lui organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 9 givenname: Irene Oi-Lin surname: Ng fullname: Ng, Irene Oi-Lin email: iolng@hku.hk organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong – sequence: 10 givenname: Chun-Ming surname: Wong fullname: Wong, Chun-Ming email: jackwong@pathology.hku.hk organization: State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28532996$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkkFvEzEQhS1URNPAH-CALHHhkjD2rjdehCpVVWmRKiGlcLa8zmzrsGsvtjci_x6vUnqIRDnNHL43Hr83Z-TEeYeEvGWwZMCqj9vl9gGHJQe2WoJYAhMvyIxVAAuoSnZCZhmSC8lX8pScxbgFgALq8hU55VIUvK6rGfl9Y2PKY2mP6WHfpaBdbDHoiPS61nQIvvcJI-3sDgM12plcNrjDzg89ukSbPcXB3qPDZA2NtkNnrLunvqVp7H2gcRyGgDHmdqLo-mK9vrorXpOXre4ivnmsc_Ljy9X3y5vF7bfrr5cXtwsjRJUWKNqmYYhSSpBFITgIQF1iWTKoZSGattow0YI2dY2yhFVRVRVyY5huciOLOflwmJu_8mvEmFRvo8Gu0w79GBWrs32iECXL6PsjdOvH4PJ2ioPkXJYsrzAn7x6pselxo4Zgex326q-nGeAHwAQfY8D2CWGgpuDUVk3BqSk4BULl4LJIHomMTTpZ73Iktnte-vkgxWzjzmJQ0dicAm5sQJPUxtvn5edHctNZZ43ufuIe45MFTEWuQN1NRzXdFFsVOQzG84BP_x7wv9f_ANYH3Cw |
CitedBy_id | crossref_primary_10_3390_ijms19123978 crossref_primary_10_34172_bi_2021_23 crossref_primary_10_1038_s41392_020_00252_1 crossref_primary_10_1158_2159_8290_CD_19_0532 crossref_primary_10_1080_14728222_2023_2259096 crossref_primary_10_1158_1535_7163_MCT_20_0474 crossref_primary_10_1016_j_ejcb_2023_151299 crossref_primary_10_1038_s41392_020_0147_5 crossref_primary_10_3389_fimmu_2022_914612 crossref_primary_10_1016_j_jhepr_2020_100167 crossref_primary_10_4254_wjh_v13_i9_979 crossref_primary_10_3389_fgene_2022_835265 crossref_primary_10_3390_cancers16122175 crossref_primary_10_1016_j_ejphar_2020_173827 crossref_primary_10_32604_biocell_2023_025250 crossref_primary_10_1002_mco2_292 crossref_primary_10_2147_JHC_S456683 crossref_primary_10_1016_j_scitotenv_2019_05_144 crossref_primary_10_3390_ijms22063137 crossref_primary_10_3390_life11101082 crossref_primary_10_3724_abbs_2022069 crossref_primary_10_1186_s13148_022_01393_6 crossref_primary_10_1016_j_compbiomed_2022_105896 crossref_primary_10_3390_ijms25010334 crossref_primary_10_1016_j_semcancer_2021_07_017 crossref_primary_10_1186_s13046_024_03036_5 crossref_primary_10_1002_1878_0261_13417 crossref_primary_10_1016_j_cmet_2020_12_010 crossref_primary_10_1002_cac2_12366 crossref_primary_10_1016_j_ejmech_2019_06_072 crossref_primary_10_1038_s41388_022_02279_w crossref_primary_10_3389_fcell_2022_806989 crossref_primary_10_1016_j_humpath_2017_11_003 crossref_primary_10_34133_2022_9814652 crossref_primary_10_1007_s12033_024_01130_9 crossref_primary_10_1186_s13046_022_02297_2 crossref_primary_10_3390_ijms21238894 crossref_primary_10_1038_s42003_021_02405_6 crossref_primary_10_1038_s41419_020_03381_1 crossref_primary_10_1016_j_jhep_2019_03_007 crossref_primary_10_1016_j_apsb_2023_12_002 crossref_primary_10_1177_2516865719839011 crossref_primary_10_3390_jcm9020360 crossref_primary_10_3390_genes12050622 crossref_primary_10_1002_adbi_202300083 crossref_primary_10_3389_fimmu_2022_1043667 crossref_primary_10_3390_livers3010008 crossref_primary_10_3390_cancers15051371 crossref_primary_10_1248_bpb_b21_00241 crossref_primary_10_1186_s43556_022_00095_y crossref_primary_10_3390_cancers13205250 crossref_primary_10_3390_cancers15102823 crossref_primary_10_1002_mco2_261 crossref_primary_10_1016_j_gene_2022_146595 crossref_primary_10_3390_pharmaceutics14071380 crossref_primary_10_1016_j_cca_2020_05_016 crossref_primary_10_1016_j_drudis_2017_07_008 crossref_primary_10_1186_s12943_020_01172_y crossref_primary_10_5483_BMBRep_2020_53_11_055 crossref_primary_10_3390_cancers13102376 crossref_primary_10_1111_febs_16334 crossref_primary_10_1186_s11658_022_00336_6 crossref_primary_10_3390_cells12192367 crossref_primary_10_1111_cge_13589 crossref_primary_10_1042_CS20190666 crossref_primary_10_1002_hep_30414 crossref_primary_10_1016_j_bbcan_2020_188498 crossref_primary_10_1038_s41419_021_03853_y crossref_primary_10_1016_j_ejmech_2021_113588 crossref_primary_10_3390_ijms23073911 crossref_primary_10_3390_jcm10081715 crossref_primary_10_3390_cimb46110711 crossref_primary_10_1186_s13578_021_00663_9 crossref_primary_10_1002_hep_29683 crossref_primary_10_1158_0008_5472_CAN_18_2676 crossref_primary_10_1016_j_nantod_2022_101734 crossref_primary_10_1002_2211_5463_12724 crossref_primary_10_1142_S0218127423500062 crossref_primary_10_1158_1541_7786_MCR_20_0557 crossref_primary_10_1016_j_cyto_2022_155967 crossref_primary_10_3390_ijms24032805 crossref_primary_10_4254_wjh_v16_i5_703 crossref_primary_10_3390_cancers14122855 crossref_primary_10_3389_fonc_2021_685065 crossref_primary_10_1016_j_jncc_2022_09_002 crossref_primary_10_1080_00498254_2018_1490044 crossref_primary_10_1016_j_heliyon_2022_e10416 crossref_primary_10_1097_MD_0000000000024449 crossref_primary_10_3389_fphar_2022_900825 crossref_primary_10_1155_2021_6650781 crossref_primary_10_1111_jvh_14044 crossref_primary_10_1002_hep_31141 crossref_primary_10_1038_s41392_024_02075_w crossref_primary_10_1038_s41416_025_02969_8 crossref_primary_10_1074_jbc_RA117_000623 crossref_primary_10_1002_jbt_22674 crossref_primary_10_1021_acsami_9b16323 crossref_primary_10_1002_advs_202102051 crossref_primary_10_1002_jcla_24090 crossref_primary_10_1089_jir_2022_0183 crossref_primary_10_3389_fonc_2024_1246308 crossref_primary_10_3390_biom14080986 crossref_primary_10_1038_s41388_021_01799_1 crossref_primary_10_1186_s12943_018_0847_4 crossref_primary_10_1111_cas_14173 crossref_primary_10_1186_s40164_020_00164_4 crossref_primary_10_3389_fgene_2022_897123 crossref_primary_10_3390_ijms22126264 crossref_primary_10_1002_hep_30168 |
Cites_doi | 10.1002/path.2491 10.1038/onc.2008.377 10.1002/hep.28304 10.1016/S0165-4608(03)00103-1 10.1002/gcc.20136 10.1038/ng.297 10.2353/ajpath.2009.080874 10.15252/emmm.201303675 10.1128/MCB.00813-13 10.1002/hep.25679 10.1038/ncb1353 10.1136/gutjnl-2013-306627 10.1016/S0959-8049(98)00430-4 10.1016/j.molcel.2010.06.008 10.1038/nrg2005 10.1111/j.1478-3231.2007.01637.x 10.1056/NEJMoa0708857 10.1053/gast.2000.9373 10.1038/sj.onc.1206774 10.1038/sj.bjc.6602448 10.1002/ijc.29210 10.1016/j.cmet.2013.11.004 10.1126/science.1063127 10.1073/pnas.95.25.14811 10.1371/journal.pone.0016702 10.1002/pros.21038 10.1172/JCI57349 10.1186/1476-4598-13-172 10.1038/cdd.2015.90 10.1101/gad.989402 10.1016/j.cellsig.2006.11.005 10.1097/CAD.0b013e32835ffdbb 10.1182/blood.V98.9.2837 10.1016/j.bbrc.2015.01.068 10.1038/nrc2809 10.1371/journal.pone.0023230 10.1158/0008-5472.CAN-10-0833 10.1186/1476-4598-13-189 10.1038/nrd3674 10.1038/nchembio.599 10.1016/j.molcel.2007.01.017 10.1016/j.febslet.2012.03.020 10.1038/sj.onc.1206235 10.1002/hep.26083 10.1074/jbc.M307215200 |
ContentType | Journal Article |
Copyright | 2017 European Association for the Study of the Liver Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Copyright Elsevier Science Ltd. Oct 2017 |
Copyright_xml | – notice: 2017 European Association for the Study of the Liver – notice: Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. – notice: Copyright Elsevier Science Ltd. Oct 2017 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
DOI | 10.1016/j.jhep.2017.05.015 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0641 |
EndPage | 769 |
ExternalDocumentID | 28532996 10_1016_j_jhep_2017_05_015 S0168827817320512 1_s2_0_S0168827817320512 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 D-I DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 |
ID | FETCH-LOGICAL-c556t-e5fbb1ee888083352050ea4e44109835bf6d15f0ac99e84073666e2cc1ab66e83 |
IEDL.DBID | .~1 |
ISSN | 0168-8278 1600-0641 |
IngestDate | Fri Jul 11 06:06:09 EDT 2025 Fri Jul 25 06:04:20 EDT 2025 Wed Feb 19 02:35:50 EST 2025 Thu Apr 24 23:00:08 EDT 2025 Tue Jul 01 02:33:53 EDT 2025 Fri Feb 23 02:32:17 EST 2024 Sun Feb 23 10:19:18 EST 2025 Tue Aug 26 16:56:39 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Epigenetics Gene amplification Histone modifications miR-1 RARRES3 G9a |
Language | English |
License | Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c556t-e5fbb1ee888083352050ea4e44109835bf6d15f0ac99e84073666e2cc1ab66e83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 28532996 |
PQID | 2082284183 |
PQPubID | 2047556 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_1901753541 proquest_journals_2082284183 pubmed_primary_28532996 crossref_primary_10_1016_j_jhep_2017_05_015 crossref_citationtrail_10_1016_j_jhep_2017_05_015 elsevier_sciencedirect_doi_10_1016_j_jhep_2017_05_015 elsevier_clinicalkeyesjournals_1_s2_0_S0168827817320512 elsevier_clinicalkey_doi_10_1016_j_jhep_2017_05_015 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-10-01 |
PublicationDateYYYYMMDD | 2017-10-01 |
PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Amsterdam |
PublicationTitle | Journal of hepatology |
PublicationTitleAlternate | J Hepatol |
PublicationYear | 2017 |
Publisher | Elsevier B.V Elsevier Science Ltd |
Publisher_xml | – name: Elsevier B.V – name: Elsevier Science Ltd |
References | Wong, Wong, Ng, Au, Ko, Ng (b0190) 2011; 6 Pang, Ng, Fan, Kwong (b0170) 2003; 146 Sonoki, Harder, Horsman, Karran, Taniguchi, Willis (b0180) 2001; 98 Ren, Qiu, Cui, Fu (b0145) 2015; 459 Chochi, Kawauchi, Nakao, Furuya, Hashimoto, Oga (b0175) 2009; 217 Bruix, Gores, Mazzaferro (b0010) 2014; 63 Moinzadeh, Breuhahn, Stutzer, Schirmacher (b0165) 2005; 92 Seligson, Horvath, McBrian, Mah, Yu, Tze (b0075) 2009; 174 Sturniolo, Dashti, Deucher, Rorke, Broome, Chandraratna (b0230) 2003; 278 Chen, Yeh, Chen, Wu, Hsu, Tsai (b0155) 2000; 119 Ferlay, Soerjomataram, Dikshit, Eser, Mathers, Rebelo (b0005) 2015; 136 Lin, Sheu, Huang, Lee, Chen, Wang (b0160) 1999; 35 Gorringe, Boussioutas, Bowtell (b0185) 2005; 42 Wong, Wei, Law, Ho, Tsang, Au (b0055) 2016; 63 Lee, Kim, Kim, Lee (b0195) 2009; 28 Feldman, Gerson, Fang, Li, Zhang, Shinkai (b0060) 2006; 8 Wang, Dubois (b0215) 2010; 10 Wen, Wu, Shinkai, Irizarry, Feinberg (b0065) 2009; 41 Higuchi, Chandraratna, Hong, Lotan (b0110) 2003; 22 Wong, Ng (b0025) 2008; 28 Hua, Wang, Chen, Wei, Chen, Ko (b0135) 2014; 13 Arrowsmith, Bountra, Fish, Lee, Schapira (b0030) 2012; 11 Tsai, Shyu, Jiang (b0105) 2007; 19 Lu, Tian, Salwen, Chlenski, Godley, Raj (b0140) 2013; 24 Vedadi, Barsyte-Lovejoy, Liu, Rival-Gervier, Allali-Hassani, Labrie (b0090) 2011; 7 Hsu, Jiang, Chang, Eckert, Scharadin, Chang (b0225) 2015; 22 Momparler (b0020) 2003; 22 Llovet, Ricci, Mazzaferro, Hilgard, Gane, Blanc (b0015) 2008; 359 Fan, Tsang, Tam, Au, Wong, Wei (b0050) 2013; 57 Ellinger, Kahl, von der Gathen, Rogenhofer, Heukamp, Gutgemann (b0080) 2010; 70 Tachibana, Sugimoto, Nozaki, Ueda, Ohta, Ohki (b0070) 2002; 16 Kubicek, O'Sullivan, August, Hickey, Zhang, Teodoro (b0095) 2007; 25 Scharadin, Jiang, Jans, Rorke, Eckert (b0115) 2011; 6 Esteller (b0035) 2007; 8 DiSepio, Ghosn, Eckert, Deucher, Robinson, Duvic (b0100) 1998; 95 Dong, Wu, Yao, Wang, Yu, Rychahou (b0130) 2012; 122 Au, Wong, Lee, Fan, Tsang, Ng (b0045) 2012; 56 Artal-Martinez de Narvajas, Gomez, Zhang, Mann, Taoda, Gorman (b0205) 2013; 33 Lee, Kim, Kim, Kim, Choi, Lee (b0200) 2010; 39 Hsu, Chu, Jiang, Hung, Ni, Lin (b0220) 2012; 586 Chen, Hua, Kao, Chi, Wei, Johansson (b0125) 2010; 70 Ding, Li, Wang, Zhao, Choi, Yang (b0210) 2013; 18 Jenuwein, Allis (b0040) 2001; 293 Morales, Arenas, Urosevic, Guiu, Fernandez, Planet (b0120) 2014; 6 Li, Hua, Lin, Su, Ko, Hsiao (b0150) 2014; 13 Tsai (10.1016/j.jhep.2017.05.015_b0105) 2007; 19 Momparler (10.1016/j.jhep.2017.05.015_b0020) 2003; 22 Feldman (10.1016/j.jhep.2017.05.015_b0060) 2006; 8 Chochi (10.1016/j.jhep.2017.05.015_b0175) 2009; 217 Arrowsmith (10.1016/j.jhep.2017.05.015_b0030) 2012; 11 Lee (10.1016/j.jhep.2017.05.015_b0195) 2009; 28 Llovet (10.1016/j.jhep.2017.05.015_b0015) 2008; 359 Ellinger (10.1016/j.jhep.2017.05.015_b0080) 2010; 70 Scharadin (10.1016/j.jhep.2017.05.015_b0115) 2011; 6 Wong (10.1016/j.jhep.2017.05.015_b0190) 2011; 6 Higuchi (10.1016/j.jhep.2017.05.015_b0110) 2003; 22 Tachibana (10.1016/j.jhep.2017.05.015_b0070) 2002; 16 Wong (10.1016/j.jhep.2017.05.015_b0025) 2008; 28 Hua (10.1016/j.jhep.2017.05.015_b0135) 2014; 13 Au (10.1016/j.jhep.2017.05.015_b0045) 2012; 56 Lin (10.1016/j.jhep.2017.05.015_b0160) 1999; 35 Chen (10.1016/j.jhep.2017.05.015_b0155) 2000; 119 Hsu (10.1016/j.jhep.2017.05.015_b0225) 2015; 22 Vedadi (10.1016/j.jhep.2017.05.015_b0090) 2011; 7 Morales (10.1016/j.jhep.2017.05.015_b0120) 2014; 6 Sonoki (10.1016/j.jhep.2017.05.015_b0180) 2001; 98 Fan (10.1016/j.jhep.2017.05.015_b0050) 2013; 57 Sturniolo (10.1016/j.jhep.2017.05.015_b0230) 2003; 278 Gorringe (10.1016/j.jhep.2017.05.015_b0185) 2005; 42 Seligson (10.1016/j.jhep.2017.05.015_b0075) 2009; 174 Li (10.1016/j.jhep.2017.05.015_b0150) 2014; 13 Lu (10.1016/j.jhep.2017.05.015_b0140) 2013; 24 Esteller (10.1016/j.jhep.2017.05.015_b0035) 2007; 8 Ferlay (10.1016/j.jhep.2017.05.015_b0005) 2015; 136 Wen (10.1016/j.jhep.2017.05.015_b0065) 2009; 41 Chen (10.1016/j.jhep.2017.05.015_b0125) 2010; 70 Wang (10.1016/j.jhep.2017.05.015_b0215) 2010; 10 Bruix (10.1016/j.jhep.2017.05.015_b0010) 2014; 63 Jenuwein (10.1016/j.jhep.2017.05.015_b0040) 2001; 293 Ding (10.1016/j.jhep.2017.05.015_b0210) 2013; 18 Kubicek (10.1016/j.jhep.2017.05.015_b0095) 2007; 25 Pang (10.1016/j.jhep.2017.05.015_b0170) 2003; 146 Moinzadeh (10.1016/j.jhep.2017.05.015_b0165) 2005; 92 Dong (10.1016/j.jhep.2017.05.015_b0130) 2012; 122 Lee (10.1016/j.jhep.2017.05.015_b0200) 2010; 39 Hsu (10.1016/j.jhep.2017.05.015_b0220) 2012; 586 Ren (10.1016/j.jhep.2017.05.015_b0145) 2015; 459 Wong (10.1016/j.jhep.2017.05.015_b0055) 2016; 63 DiSepio (10.1016/j.jhep.2017.05.015_b0100) 1998; 95 Artal-Martinez de Narvajas (10.1016/j.jhep.2017.05.015_b0205) 2013; 33 |
References_xml | – volume: 70 start-page: 61 year: 2010 end-page: 69 ident: b0080 article-title: Global levels of histone modifications predict prostate cancer recurrence publication-title: Prostate – volume: 6 start-page: e16702 year: 2011 ident: b0190 article-title: Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery publication-title: PLoS One – volume: 8 start-page: 188 year: 2006 end-page: 194 ident: b0060 article-title: G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis publication-title: Nat Cell Biol – volume: 22 start-page: 4627 year: 2003 end-page: 4635 ident: b0110 article-title: Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype publication-title: Oncogene – volume: 146 start-page: 8 year: 2003 end-page: 15 ident: b0170 article-title: Clinicopathologic significance of genetic alterations in hepatocellular carcinoma publication-title: Cancer Genet Cytogenet – volume: 63 start-page: 474 year: 2016 end-page: 487 ident: b0055 article-title: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis publication-title: Hepatology – volume: 41 start-page: 246 year: 2009 end-page: 250 ident: b0065 article-title: Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells publication-title: Nat Genet – volume: 63 start-page: 844 year: 2014 end-page: 855 ident: b0010 article-title: Hepatocellular carcinoma: clinical frontiers and perspectives publication-title: Gut – volume: 28 start-page: 160 year: 2008 end-page: 174 ident: b0025 article-title: Molecular pathogenesis of hepatocellular carcinoma publication-title: Liver Int – volume: 56 start-page: 622 year: 2012 end-page: 631 ident: b0045 article-title: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis publication-title: Hepatology – volume: 70 start-page: 7830 year: 2010 end-page: 7840 ident: b0125 article-title: H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM publication-title: Cancer Res – volume: 22 start-page: 6479 year: 2003 end-page: 6483 ident: b0020 article-title: Cancer epigenetics publication-title: Oncogene – volume: 98 start-page: 2837 year: 2001 end-page: 2844 ident: b0180 article-title: Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies publication-title: Blood – volume: 10 start-page: 181 year: 2010 end-page: 193 ident: b0215 article-title: Eicosanoids and cancer publication-title: Nat Rev Cancer – volume: 19 start-page: 989 year: 2007 end-page: 999 ident: b0105 article-title: RIG1 suppresses Ras activation and induces cellular apoptosis at the Golgi apparatus publication-title: Cell Signal – volume: 119 start-page: 431 year: 2000 end-page: 440 ident: b0155 article-title: Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma publication-title: Gastroenterology – volume: 18 start-page: 896 year: 2013 end-page: 907 ident: b0210 article-title: The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation publication-title: Cell Metab – volume: 136 start-page: E359 year: 2015 end-page: E386 ident: b0005 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer – volume: 24 start-page: 484 year: 2013 end-page: 493 ident: b0140 article-title: Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells publication-title: Anticancer Drugs – volume: 16 start-page: 1779 year: 2002 end-page: 1791 ident: b0070 article-title: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis publication-title: Genes Dev – volume: 39 start-page: 71 year: 2010 end-page: 85 ident: b0200 article-title: Negative regulation of hypoxic responses via induced Reptin methylation publication-title: Mol Cell – volume: 22 start-page: 1561 year: 2015 ident: b0225 article-title: Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells publication-title: Cell Death Differ – volume: 278 start-page: 48066 year: 2003 end-page: 48073 ident: b0230 article-title: A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase publication-title: J Biol Chem – volume: 33 start-page: 3983 year: 2013 end-page: 3993 ident: b0205 article-title: Epigenetic regulation of autophagy by the methyltransferase G9a publication-title: Mol Cell Biol – volume: 8 start-page: 286 year: 2007 end-page: 298 ident: b0035 article-title: Cancer epigenomics: DNA methylomes and histone-modification maps publication-title: Nat Rev Genet – volume: 293 start-page: 1074 year: 2001 end-page: 1080 ident: b0040 article-title: Translating the histone code publication-title: Science – volume: 586 start-page: 1287 year: 2012 end-page: 1293 ident: b0220 article-title: Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines publication-title: FEBS Lett – volume: 57 start-page: 637 year: 2013 end-page: 647 ident: b0050 article-title: Histone lysine methyltransferase, suppressor of variegation 3–9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b publication-title: Hepatology – volume: 174 start-page: 1619 year: 2009 end-page: 1628 ident: b0075 article-title: Global levels of histone modifications predict prognosis in different cancers publication-title: Am J Pathol – volume: 35 start-page: 652 year: 1999 end-page: 658 ident: b0160 article-title: Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan publication-title: Eur J Cancer – volume: 42 start-page: 247 year: 2005 end-page: 259 ident: b0185 article-title: Melbourne Gastric Cancer Group PMMAF. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization publication-title: Genes Chromosom Cancer – volume: 13 start-page: 189 year: 2014 ident: b0135 article-title: The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis publication-title: Mol Cancer – volume: 28 start-page: 184 year: 2009 end-page: 194 ident: b0195 article-title: Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells publication-title: Oncogene – volume: 6 start-page: e23230 year: 2011 ident: b0115 article-title: TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells publication-title: PLoS One – volume: 459 start-page: 10 year: 2015 end-page: 17 ident: b0145 article-title: Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma publication-title: Biochem Biophys Res Commun – volume: 13 start-page: 172 year: 2014 ident: b0150 article-title: Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma publication-title: Mol Cancer – volume: 359 start-page: 378 year: 2008 end-page: 390 ident: b0015 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med – volume: 11 start-page: 384 year: 2012 end-page: 400 ident: b0030 article-title: Epigenetic protein families: a new frontier for drug discovery publication-title: Nat Rev Drug Discovery – volume: 7 start-page: 566 year: 2011 end-page: 574 ident: b0090 article-title: A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells publication-title: Nat Chem Biol – volume: 217 start-page: 677 year: 2009 end-page: 684 ident: b0175 article-title: A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study publication-title: J Pathol – volume: 95 start-page: 14811 year: 1998 end-page: 14815 ident: b0100 article-title: Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene publication-title: Proc Natl Acad Sci USA – volume: 6 start-page: 865 year: 2014 end-page: 881 ident: b0120 article-title: RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation publication-title: EMBO Mol Med – volume: 25 start-page: 473 year: 2007 end-page: 481 ident: b0095 article-title: Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase publication-title: Mol Cell – volume: 122 start-page: 1469 year: 2012 end-page: 1486 ident: b0130 article-title: G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer publication-title: J Clin Invest – volume: 92 start-page: 935 year: 2005 end-page: 941 ident: b0165 article-title: Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade–results of an explorative CGH meta-analysis publication-title: Br J Cancer – volume: 217 start-page: 677 year: 2009 ident: 10.1016/j.jhep.2017.05.015_b0175 article-title: A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study publication-title: J Pathol doi: 10.1002/path.2491 – volume: 28 start-page: 184 year: 2009 ident: 10.1016/j.jhep.2017.05.015_b0195 article-title: Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells publication-title: Oncogene doi: 10.1038/onc.2008.377 – volume: 63 start-page: 474 year: 2016 ident: 10.1016/j.jhep.2017.05.015_b0055 article-title: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis publication-title: Hepatology doi: 10.1002/hep.28304 – volume: 146 start-page: 8 year: 2003 ident: 10.1016/j.jhep.2017.05.015_b0170 article-title: Clinicopathologic significance of genetic alterations in hepatocellular carcinoma publication-title: Cancer Genet Cytogenet doi: 10.1016/S0165-4608(03)00103-1 – volume: 42 start-page: 247 year: 2005 ident: 10.1016/j.jhep.2017.05.015_b0185 article-title: Melbourne Gastric Cancer Group PMMAF. Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization publication-title: Genes Chromosom Cancer doi: 10.1002/gcc.20136 – volume: 41 start-page: 246 year: 2009 ident: 10.1016/j.jhep.2017.05.015_b0065 article-title: Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells publication-title: Nat Genet doi: 10.1038/ng.297 – volume: 174 start-page: 1619 year: 2009 ident: 10.1016/j.jhep.2017.05.015_b0075 article-title: Global levels of histone modifications predict prognosis in different cancers publication-title: Am J Pathol doi: 10.2353/ajpath.2009.080874 – volume: 6 start-page: 865 year: 2014 ident: 10.1016/j.jhep.2017.05.015_b0120 article-title: RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation publication-title: EMBO Mol Med doi: 10.15252/emmm.201303675 – volume: 33 start-page: 3983 year: 2013 ident: 10.1016/j.jhep.2017.05.015_b0205 article-title: Epigenetic regulation of autophagy by the methyltransferase G9a publication-title: Mol Cell Biol doi: 10.1128/MCB.00813-13 – volume: 56 start-page: 622 year: 2012 ident: 10.1016/j.jhep.2017.05.015_b0045 article-title: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis publication-title: Hepatology doi: 10.1002/hep.25679 – volume: 8 start-page: 188 year: 2006 ident: 10.1016/j.jhep.2017.05.015_b0060 article-title: G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis publication-title: Nat Cell Biol doi: 10.1038/ncb1353 – volume: 63 start-page: 844 year: 2014 ident: 10.1016/j.jhep.2017.05.015_b0010 article-title: Hepatocellular carcinoma: clinical frontiers and perspectives publication-title: Gut doi: 10.1136/gutjnl-2013-306627 – volume: 35 start-page: 652 year: 1999 ident: 10.1016/j.jhep.2017.05.015_b0160 article-title: Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan publication-title: Eur J Cancer doi: 10.1016/S0959-8049(98)00430-4 – volume: 39 start-page: 71 year: 2010 ident: 10.1016/j.jhep.2017.05.015_b0200 article-title: Negative regulation of hypoxic responses via induced Reptin methylation publication-title: Mol Cell doi: 10.1016/j.molcel.2010.06.008 – volume: 8 start-page: 286 year: 2007 ident: 10.1016/j.jhep.2017.05.015_b0035 article-title: Cancer epigenomics: DNA methylomes and histone-modification maps publication-title: Nat Rev Genet doi: 10.1038/nrg2005 – volume: 28 start-page: 160 year: 2008 ident: 10.1016/j.jhep.2017.05.015_b0025 article-title: Molecular pathogenesis of hepatocellular carcinoma publication-title: Liver Int doi: 10.1111/j.1478-3231.2007.01637.x – volume: 359 start-page: 378 year: 2008 ident: 10.1016/j.jhep.2017.05.015_b0015 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – volume: 119 start-page: 431 year: 2000 ident: 10.1016/j.jhep.2017.05.015_b0155 article-title: Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma publication-title: Gastroenterology doi: 10.1053/gast.2000.9373 – volume: 22 start-page: 6479 year: 2003 ident: 10.1016/j.jhep.2017.05.015_b0020 article-title: Cancer epigenetics publication-title: Oncogene doi: 10.1038/sj.onc.1206774 – volume: 92 start-page: 935 year: 2005 ident: 10.1016/j.jhep.2017.05.015_b0165 article-title: Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade–results of an explorative CGH meta-analysis publication-title: Br J Cancer doi: 10.1038/sj.bjc.6602448 – volume: 136 start-page: E359 year: 2015 ident: 10.1016/j.jhep.2017.05.015_b0005 article-title: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 publication-title: Int J Cancer doi: 10.1002/ijc.29210 – volume: 18 start-page: 896 year: 2013 ident: 10.1016/j.jhep.2017.05.015_b0210 article-title: The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation publication-title: Cell Metab doi: 10.1016/j.cmet.2013.11.004 – volume: 293 start-page: 1074 year: 2001 ident: 10.1016/j.jhep.2017.05.015_b0040 article-title: Translating the histone code publication-title: Science doi: 10.1126/science.1063127 – volume: 95 start-page: 14811 year: 1998 ident: 10.1016/j.jhep.2017.05.015_b0100 article-title: Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.25.14811 – volume: 6 start-page: e16702 year: 2011 ident: 10.1016/j.jhep.2017.05.015_b0190 article-title: Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery publication-title: PLoS One doi: 10.1371/journal.pone.0016702 – volume: 70 start-page: 61 year: 2010 ident: 10.1016/j.jhep.2017.05.015_b0080 article-title: Global levels of histone modifications predict prostate cancer recurrence publication-title: Prostate doi: 10.1002/pros.21038 – volume: 122 start-page: 1469 year: 2012 ident: 10.1016/j.jhep.2017.05.015_b0130 article-title: G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer publication-title: J Clin Invest doi: 10.1172/JCI57349 – volume: 13 start-page: 172 year: 2014 ident: 10.1016/j.jhep.2017.05.015_b0150 article-title: Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma publication-title: Mol Cancer doi: 10.1186/1476-4598-13-172 – volume: 22 start-page: 1561 year: 2015 ident: 10.1016/j.jhep.2017.05.015_b0225 article-title: Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells publication-title: Cell Death Differ doi: 10.1038/cdd.2015.90 – volume: 16 start-page: 1779 year: 2002 ident: 10.1016/j.jhep.2017.05.015_b0070 article-title: G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis publication-title: Genes Dev doi: 10.1101/gad.989402 – volume: 19 start-page: 989 year: 2007 ident: 10.1016/j.jhep.2017.05.015_b0105 article-title: RIG1 suppresses Ras activation and induces cellular apoptosis at the Golgi apparatus publication-title: Cell Signal doi: 10.1016/j.cellsig.2006.11.005 – volume: 24 start-page: 484 year: 2013 ident: 10.1016/j.jhep.2017.05.015_b0140 article-title: Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells publication-title: Anticancer Drugs doi: 10.1097/CAD.0b013e32835ffdbb – volume: 98 start-page: 2837 year: 2001 ident: 10.1016/j.jhep.2017.05.015_b0180 article-title: Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies publication-title: Blood doi: 10.1182/blood.V98.9.2837 – volume: 459 start-page: 10 year: 2015 ident: 10.1016/j.jhep.2017.05.015_b0145 article-title: Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2015.01.068 – volume: 10 start-page: 181 year: 2010 ident: 10.1016/j.jhep.2017.05.015_b0215 article-title: Eicosanoids and cancer publication-title: Nat Rev Cancer doi: 10.1038/nrc2809 – volume: 6 start-page: e23230 year: 2011 ident: 10.1016/j.jhep.2017.05.015_b0115 article-title: TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells publication-title: PLoS One doi: 10.1371/journal.pone.0023230 – volume: 70 start-page: 7830 year: 2010 ident: 10.1016/j.jhep.2017.05.015_b0125 article-title: H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-0833 – volume: 13 start-page: 189 year: 2014 ident: 10.1016/j.jhep.2017.05.015_b0135 article-title: The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis publication-title: Mol Cancer doi: 10.1186/1476-4598-13-189 – volume: 11 start-page: 384 year: 2012 ident: 10.1016/j.jhep.2017.05.015_b0030 article-title: Epigenetic protein families: a new frontier for drug discovery publication-title: Nat Rev Drug Discovery doi: 10.1038/nrd3674 – volume: 7 start-page: 566 year: 2011 ident: 10.1016/j.jhep.2017.05.015_b0090 article-title: A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells publication-title: Nat Chem Biol doi: 10.1038/nchembio.599 – volume: 25 start-page: 473 year: 2007 ident: 10.1016/j.jhep.2017.05.015_b0095 article-title: Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase publication-title: Mol Cell doi: 10.1016/j.molcel.2007.01.017 – volume: 586 start-page: 1287 year: 2012 ident: 10.1016/j.jhep.2017.05.015_b0220 article-title: Expression of the class II tumor suppressor gene RIG1 is directly regulated by p53 tumor suppressor in cancer cell lines publication-title: FEBS Lett doi: 10.1016/j.febslet.2012.03.020 – volume: 22 start-page: 4627 year: 2003 ident: 10.1016/j.jhep.2017.05.015_b0110 article-title: Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype publication-title: Oncogene doi: 10.1038/sj.onc.1206235 – volume: 57 start-page: 637 year: 2013 ident: 10.1016/j.jhep.2017.05.015_b0050 article-title: Histone lysine methyltransferase, suppressor of variegation 3–9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b publication-title: Hepatology doi: 10.1002/hep.26083 – volume: 278 start-page: 48066 year: 2003 ident: 10.1016/j.jhep.2017.05.015_b0230 article-title: A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase publication-title: J Biol Chem doi: 10.1074/jbc.M307215200 |
SSID | ssj0003094 |
Score | 2.564706 |
Snippet | [Display omitted]
•G9a was frequently upregulated in human HCC and associated with HCC aggressiveness.•G9a promoted HCC growth and metastasis both in vitro and... Graphical abstract Deregulation of G9a in human HCC. G9a was frequently up-regulated in human HCC and implicated in HCC tumorigenesis and metastasis. The... Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human HCC. G9s is an... Background & Aims Hepatocellular carcinoma (HCC) is a major leading cause of cancer mortality worldwide. Epigenetic deregulation is a common trait of human... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 758 |
SubjectTerms | 3' Untranslated Regions Animal models Animals Carcinogenesis Carcinogens Carcinoma, Hepatocellular - enzymology Carcinoma, Hepatocellular - etiology Carcinoma, Hepatocellular - genetics Cell Line, Tumor Cell proliferation Chromosome 6 Copy number CRISPR Enzymes Epigenesis, Genetic Epigenetics G9a Gastroenterology and Hepatology Gene amplification Gene Dosage Gene expression Gene Knockdown Techniques Gene Knockout Techniques Gene Silencing Genes, Tumor Suppressor Hepatocellular carcinoma Histocompatibility Antigens - genetics Histocompatibility Antigens - metabolism Histone methyltransferase Histone modifications Histone-Lysine N-Methyltransferase - genetics Histone-Lysine N-Methyltransferase - metabolism Humans Liver cancer Liver Neoplasms - enzymology Liver Neoplasms - etiology Liver Neoplasms - genetics Liver Neoplasms, Experimental - enzymology Liver Neoplasms, Experimental - etiology Liver Neoplasms, Experimental - genetics Metastases Mice Mice, Nude MicroRNAs - genetics MicroRNAs - metabolism miR-1 Post-transcription RARRES3 Receptors, Retinoic Acid - antagonists & inhibitors Receptors, Retinoic Acid - genetics Ribonucleic acid RNA RNA, Messenger - genetics RNA, Messenger - metabolism RNA, Neoplasm - genetics RNA, Neoplasm - metabolism RNA-mediated interference Tumor suppressor genes Up-Regulation |
Title | Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3 |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0168827817320512 https://www.clinicalkey.es/playcontent/1-s2.0-S0168827817320512 https://dx.doi.org/10.1016/j.jhep.2017.05.015 https://www.ncbi.nlm.nih.gov/pubmed/28532996 https://www.proquest.com/docview/2082284183 https://www.proquest.com/docview/1901753541 |
Volume | 67 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhhdJLSd_OCxV6K-5aliXZx2VJun0klG0DuQnJK9MN212z9kJy6W_vjCw7lDYp9OSXBsua0cwn_M2IkDeJkTnYhoqNTKs4K1MbQ5QzMTOcVxAP5dxvBnN2LqcX2cdLcblDJn0uDNIqg-_vfLr31uHOKIzmqF4sRl8BrAA8VDlTPAXTQj-cZQqt_N3PW5oHT4pQ3zuPsXVInOk4XlffHdasZKF6p7grON0FPn0QOt0jjwN6pOOug0_Ijls9JQ_Pwv_xZ-TaV_1YOYobQ98sW49K3QYiFX1fGFp77p1r6BLZGLREjW_o_JY3RO0NdTUW6MTcRtosMCUJghtdV7Td_lhvaLOtPXUWTrEVnY1noEP-nFycnnybTOOwt0JcCiHb2InKWuYcLIATn3eViMSZzAE6SgpAZbaScyaqxJRF4WARqDisc1xalsxYOMn5C7K7gu95RWgKWjZMKllZnilVGgugR81zkM0LVbmIsH5QdRkKj-P-F0vdM8yuNCpCoyJ0IjQoIiJvB5m6K7txb2ve60r3CaXgAjVEhXul1N-kXBNmcaOZblKd6D8sLSJikPzNWP_5xsPekPTwkhRr7ucZuNaIvB4ewyTHPzdm5dZb6AigNlhXioxF5GVngMOwpAC4AFPI_f_s1AF5hFcdQfGQ7LabrTsCoNXaYz-TjsmD8WT2-QseP3yanv8CtOQn1w |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB2VIgEXxDeBFowEJxTWdmI7OfRQUcqWdnsordSbcbKO2GrZjTZZwV74U_zBjhMnFYIWCam3KMkkzsx45ll5MwZ4TY1M0DdUaCQvwjjnWYhZzoTMRFGB-VCOm81gRodyeBJ_OhWna_Crq4VxtEof-9uY3kRrf2bgtTkoJ5PBZwQrCA9VwlTE0bW4Z1bu29V3XLdVW3s7aOQ3nO9-OH4_DP3WAmEuhKxDK4osY9bi-o82ZUdUUGtii-CApghKskKOmSioydPU4hpIRQjzLc9zZjI8SCJ87g24GWO4cNsmvPt5wSuJaOobiiehG56v1GlJZWdfrWuSyXy7UHFZNrwM7TZZb_ce3PVwlWy3GrkPa3b2AG6N_A_5h_CjaTMys8TtRL2a1g0MtgtMjeRjakjZkP1sRaaO_kFy52ILMr4gKpFsRWzpOoK6YkpSTVwNFGZTMi9Ivfw2X5BqWTZcXTx0d5Gj7SN0mugRnFyLxh_D-gy_5ykQjm5lmFSyyKJYqdxkiLLUOEHZJFWFDYB1StW573TuNtyY6o7SdqadIbQzhKZCoyECeNvLlG2fjyvvjjpb6a6CFWOuxjR0pZT6m5StfNioNNMV11T_4doBiF7yt9nxzzdudI6k-5dw1-Q_iTGWB_Cqv4xRxf0qMjM7X-JAECbiQlbELIAnrQP2auGI8BDEyGf_OaiXcHt4PDrQB3uH-8_hjrvSsiM3YL1eLO0morw6e9HMKgJfrnsanwPJpmEA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histone+methyltransferase+G9a+promotes+liver+cancer+development+by+epigenetic+silencing+of+tumor+suppressor+gene+RARRES3&rft.jtitle=Journal+of+hepatology&rft.au=Wei%2C+Lai&rft.au=Chiu%2C+David+Kung-Chun&rft.au=Tsang%2C+Felice+Ho-Ching&rft.au=Law%2C+Cheuk-Ting&rft.date=2017-10-01&rft.pub=Elsevier+B.V&rft.issn=0168-8278&rft.volume=67&rft.issue=4&rft.spage=758&rft.epage=769&rft_id=info:doi/10.1016%2Fj.jhep.2017.05.015&rft.externalDocID=S0168827817320512 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0168-8278&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0168-8278&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0168-8278&client=summon |